Seizures and quinolone antibiotics in children: a systematic review of adverse events.
adverse effects
infectious diseases
neonatology
neurology
paediatrics
Journal
European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
12
11
2018
revised:
29
11
2018
accepted:
13
12
2018
entrez:
6
3
2020
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
ppublish
Résumé
Quinolone antibiotics have a broad spectrum of activity including against Gram-negative organisms (especially We conducted a systematic review of the MEDLINE, EMBASE and CENTRAL databases. Any studies reporting the administration of quinolones to children and including a methodology for identifying or reporting adverse events were identified by two authors who worked independently. Data relating to study characteristics (including population, intervention, comparison and outcome data) and study quality (including the quality of adverse event reporting) were extracted. We identified 140 studies involving 21 884 children. No studies reported involving children with epilepsy and 21 studies reported the involvement of 317 children with CNS disorders. 2/317 (0.63%) children with CNS disorders developed seizures and at least 4/21 567 (0.023%) children without CNS pathology were reported to have developed seizures. The quality of adverse event reporting in included studies was low. Only 8/140 (5.71%) included studies provided details of a methodology for actively identifying adverse neurological events. Even for children with CNS disorders the risk of developing seizures in association with the use of quinolones seems to be low. Further evaluations of quinolone use in children should include methodologies for actively identifying and reporting adverse neurological events.
Sections du résumé
Background
Quinolone antibiotics have a broad spectrum of activity including against Gram-negative organisms (especially
Method
We conducted a systematic review of the MEDLINE, EMBASE and CENTRAL databases. Any studies reporting the administration of quinolones to children and including a methodology for identifying or reporting adverse events were identified by two authors who worked independently. Data relating to study characteristics (including population, intervention, comparison and outcome data) and study quality (including the quality of adverse event reporting) were extracted.
Results
We identified 140 studies involving 21 884 children. No studies reported involving children with epilepsy and 21 studies reported the involvement of 317 children with CNS disorders. 2/317 (0.63%) children with CNS disorders developed seizures and at least 4/21 567 (0.023%) children without CNS pathology were reported to have developed seizures. The quality of adverse event reporting in included studies was low. Only 8/140 (5.71%) included studies provided details of a methodology for actively identifying adverse neurological events.
Discussion
Even for children with CNS disorders the risk of developing seizures in association with the use of quinolones seems to be low. Further evaluations of quinolone use in children should include methodologies for actively identifying and reporting adverse neurological events.
Identifiants
pubmed: 32133130
doi: 10.1136/ejhpharm-2018-001805
pii: ejhpharm-2018-001805
pmc: PMC7043247
doi:
Substances chimiques
Anti-Bacterial Agents
0
Quinolones
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Pagination
60-64Subventions
Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom
Informations de copyright
© European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Neurology. 2016 May 3;86(18):1708-15
pubmed: 27053716
PLoS One. 2016 Aug 02;11(8):e0159965
pubmed: 27483163
Pediatr Infect Dis J. 2000 Nov;19(11):1060-7
pubmed: 11099086
Intensive Care Med. 2002 Apr;28(4):493-500
pubmed: 11967606
Antimicrob Agents Chemother. 1989 Oct;33(10):1704-8
pubmed: 2556076
Pediatr Infect Dis J. 2002 Jan;21(1):14-22
pubmed: 11791092
Br J Pharmacol. 1997 Oct;122(3):584-90
pubmed: 9351519
J Antimicrob Chemother. 1994 Nov;34(5):737-46
pubmed: 7706169
Pediatr Infect Dis J. 2007 Oct;26(10):879-91
pubmed: 17901792
Neurology. 2015 Oct 13;85(15):1332-41
pubmed: 26400582
BMC Med Res Methodol. 2007 Jul 05;7:32
pubmed: 17615054
Pediatr Crit Care Med. 2009 Mar;10(2):222-6
pubmed: 19057452